Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
The University of North Texas Health Science Center has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 3 distinct examiners, indicating that each pending application is being reviewed by a different person. This provides the university with a variety of examiner perspectives across its active filings, which can be beneficial for understanding different interpretations of patent law.
The pending office actions are located within 2 distinct art units, showing technical concentration at the department level. LADD, CAROLYN LOUISE is the busiest examiner, currently handling 1 pending office action. Because the pending office actions are shared among the distinct examiners, the workload is distributed with no single examiner managing more than a single matter. The presence of 2 distinct art units suggests that the university's research is focused on specific areas of biotechnology. For the practitioner, this requires tailoring arguments to different individuals while maintaining consistency across the art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LADD, CAROLYN LOUISE | 1 | 58.6% | +47.1% |
| RIGA, MICHAEL ANGELO | 1 | 56.2% | +63.0% |
| MIANO, JOSEPH PAUL | 1 | 35.7% | +63.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17309030 | PROCESS FOR ENGINEERING TARGETED NANOPARTICLES | RIGA, MICHAEL ANGELO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18726054 | DRUG REPURPOSING FOR DELAYED TREATMENT OF ISCHEMIC STROKE | LADD, CAROLYN LOUISE | — |
| 17309030 | PROCESS FOR ENGINEERING TARGETED NANOPARTICLES | RIGA, MICHAEL ANGELO | — |
| 16622823 | REPROGRAMMING FIBROBLASTS TO RETINAL CELLS | MIANO, JOSEPH PAUL | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18726054 | DRUG REPURPOSING FOR DELAYED TREATMENT OF ISCHEMIC STROKE | LADD, CAROLYN LOUISE | — | §112 | Non-Final OA | — | Pending | Jul 01, 2024 |
| 17309030 | PROCESS FOR ENGINEERING TARGETED NANOPARTICLES | RIGA, MICHAEL ANGELO | 1634 | §103§112 | Non-Final OA | — | Pending | Apr 15, 2021 |
| 16622823 | REPROGRAMMING FIBROBLASTS TO RETINAL CELLS | MIANO, JOSEPH PAUL | 1631 | §103 | Final Rejection | — | Pending | Dec 13, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUniversity of North Texas Health Science Center has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Carolyn Louise Ladd has the most, with 1 of University of North Texas Health Science Center's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
